supported by NeuroEndocrine Cancer Australia (NECA), which led to Belzutifan being listed on the PBS in December. NECA CEO Meredith Cummins said the listing was a “Christmas present”.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback